The North America Attention Deficit Hyperactivity Disorder Market would witness market growth of 3.3% CAGR during the forecast period (2022-2028).
The ADHD symptoms that appear predominantly inattentive make it challenging for the sufferer to arrange or complete a task, pay close attention to specifics, or follow directions or dialogues. The individual gets easily side-tracked or overlooks small elements of daily activities. Symptoms that are predominantly hyperactive-impulsive make the sufferer fidget and speak a lot.
Long periods of stillness are challenging for these individuals. Younger children may continually jump, run, or climb. They are also highly restless and have difficulties with impulse control. Impulsive individuals may speak suddenly, seize objects from others, or interrupt others frequently. The person needs help to follow instructions or wait their turn. Impulsiveness increases the likelihood of accidents and injury for some people.
A combination presentation of ADHD makes the person exhibit both of the signs mentioned earlier in equal measure. It is possible for a person to have different types of symptoms at different stages. Nearly 11% of school-age children have ADHD, which has become a major health issue. In three out of four cases, the symptoms last throughout adulthood. Family stress, academic failure, disturbance, depression, interpersonal connection problems, substance misuse, delinquency, unintentional accidents, and work failure are just a few of the dire consequences that are linked to ADHD.
There are some common incidences that children with ADHD may continue to experience during the transition from childhood to adulthood. These symptoms include driving issues, issues relating to peers and social circumstances, high-risk sexual conduct, and substance addiction. As these symptoms make it difficult to sustain a comparatively everyday life, it has necessitated the need for ADHD treatments.
The North America region has significantly contributed to the development of ADHD therapeutics through the number of studies and research on this topic collectively. One such survey highlighted by the Environment Protection Agency of the US stated that approximately 15% of children aged 3 to 17 in the nation were suffering from some type of neurodevelopmental disorder. The disorders included learning disabilities, cerebral palsy, intellectual disability, seizures, stammering, autism, and ADHD. Among all these neurodevelopmental disorders, children with ADHD had the highest frequency.
The US market dominated the North America Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $7 billion by 2028. The Canada market is experiencing a CAGR of 5.6% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 4.7% during (2022 - 2028).
Based on Drug Type, the market is segmented into Stimulants and Non-stimulants. Based on Stimulants Type, the market is segmented into Amphetamine, Methylphenidate, Lisdexamfetamine and Dexmethylphenidate. Based on Non-stimulants Type, the market is segmented into Atomoxetine, Guanfacine, Clonidine and Others. Based on Demographics, the market is segmented into Adults and Children. Based on Distribution Channel, the market is segmented into Retail Pharmacy and Hospital Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Attention Deficit Hyperactivity Disorder Market is Predict to reach $16.9 Billion by 2028, at a CAGR of 4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Johnson & Johnson (Johnson & Johnson Services, Inc.), Lupin Limited, Novartis AG, Takeda Pharmaceutical Company Limited, Mallinckrodt PLC, Purdue Pharma L.P., Aytu BioPharma, Inc. and Supernus Pharmaceuticals, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Stimulants
- Amphetamine
- Methylphenidate
- Lisdexamfetamine
- Dexmethylphenidate
- Non-stimulants
- Atomoxetine
- Guanfacine
- Clonidine
- Others
By Demographics
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Eli Lilly And Company
- Pfizer, Inc. (Global Blood Therapeutics, Inc.)
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Lupin Limited
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Mallinckrodt PLC
- Purdue Pharma L.P.
- Aytu BioPharma, Inc.
- Supernus Pharmaceuticals, Inc.
TABLE 1 North America Attention Deficit Hyperactivity Disorder Market, 2018 - 2021, USD Million
TABLE 2 North America Attention Deficit Hyperactivity Disorder Market, 2022 - 2028, USD Million
TABLE 3 North America Attention Deficit Hyperactivity Disorder Market by Drug Type, 2018 - 2021, USD Million
TABLE 4 North America Attention Deficit Hyperactivity Disorder Market by Drug Type, 2022 - 2028, USD Million
TABLE 5 North America Stimulants Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Stimulants Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2018 - 2021, USD Million
TABLE 8 North America Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2022 - 2028, USD Million
TABLE 9 North America Amphetamine Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Amphetamine Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Methylphenidate Market by Country, 2018 - 2021, USD Million
TABLE 12 North America Methylphenidate Market by Country, 2022 - 2028, USD Million
TABLE 13 North America Lisdexamfetamine Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Lisdexamfetamine Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Dexmethylphenidate Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Dexmethylphenidate Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Non-stimulants Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Non-stimulants Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2018 - 2021, USD Million
TABLE 20 North America Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2022 - 2028, USD Million
TABLE 21 North America Atomoxetine Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Atomoxetine Market by Country, 2022 - 2028, USD Million
TABLE 23 North America Guanfacine Market by Country, 2018 - 2021, USD Million
TABLE 24 North America Guanfacine Market by Country, 2022 - 2028, USD Million
TABLE 25 North America Clonidine Market by Country, 2018 - 2021, USD Million
TABLE 26 North America Clonidine Market by Country, 2022 - 2028, USD Million
TABLE 27 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 28 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 29 North America Attention Deficit Hyperactivity Disorder Market by Demographics, 2018 - 2021, USD Million
TABLE 30 North America Attention Deficit Hyperactivity Disorder Market by Demographics, 2022 - 2028, USD Million
TABLE 31 North America Adults Market by Country, 2018 - 2021, USD Million
TABLE 32 North America Adults Market by Country, 2022 - 2028, USD Million
TABLE 33 North America Children Market by Country, 2018 - 2021, USD Million
TABLE 34 North America Children Market by Country, 2022 - 2028, USD Million
TABLE 35 North America Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 36 North America Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 37 North America Retail Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 38 North America Retail Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 39 North America Hospital Pharmacy Market by Country, 2018 - 2021, USD Million
TABLE 40 North America Hospital Pharmacy Market by Country, 2022 - 2028, USD Million
TABLE 41 North America Attention Deficit Hyperactivity Disorder Market by Country, 2018 - 2021, USD Million
TABLE 42 North America Attention Deficit Hyperactivity Disorder Market by Country, 2022 - 2028, USD Million
TABLE 43 US Attention Deficit Hyperactivity Disorder Market, 2018 - 2021, USD Million
TABLE 44 US Attention Deficit Hyperactivity Disorder Market, 2022 - 2028, USD Million
TABLE 45 US Attention Deficit Hyperactivity Disorder Market by Drug Type, 2018 - 2021, USD Million
TABLE 46 US Attention Deficit Hyperactivity Disorder Market by Drug Type, 2022 - 2028, USD Million
TABLE 47 US Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2018 - 2021, USD Million
TABLE 48 US Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2022 - 2028, USD Million
TABLE 49 US Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2018 - 2021, USD Million
TABLE 50 US Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2022 - 2028, USD Million
TABLE 51 US Attention Deficit Hyperactivity Disorder Market by Demographics, 2018 - 2021, USD Million
TABLE 52 US Attention Deficit Hyperactivity Disorder Market by Demographics, 2022 - 2028, USD Million
TABLE 53 US Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 54 US Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 55 Canada Attention Deficit Hyperactivity Disorder Market, 2018 - 2021, USD Million
TABLE 56 Canada Attention Deficit Hyperactivity Disorder Market, 2022 - 2028, USD Million
TABLE 57 Canada Attention Deficit Hyperactivity Disorder Market by Drug Type, 2018 - 2021, USD Million
TABLE 58 Canada Attention Deficit Hyperactivity Disorder Market by Drug Type, 2022 - 2028, USD Million
TABLE 59 Canada Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2018 - 2021, USD Million
TABLE 60 Canada Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2022 - 2028, USD Million
TABLE 61 Canada Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2018 - 2021, USD Million
TABLE 62 Canada Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2022 - 2028, USD Million
TABLE 63 Canada Attention Deficit Hyperactivity Disorder Market by Demographics, 2018 - 2021, USD Million
TABLE 64 Canada Attention Deficit Hyperactivity Disorder Market by Demographics, 2022 - 2028, USD Million
TABLE 65 Canada Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 66 Canada Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 67 Mexico Attention Deficit Hyperactivity Disorder Market, 2018 - 2021, USD Million
TABLE 68 Mexico Attention Deficit Hyperactivity Disorder Market, 2022 - 2028, USD Million
TABLE 69 Mexico Attention Deficit Hyperactivity Disorder Market by Drug Type, 2018 - 2021, USD Million
TABLE 70 Mexico Attention Deficit Hyperactivity Disorder Market by Drug Type, 2022 - 2028, USD Million
TABLE 71 Mexico Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2018 - 2021, USD Million
TABLE 72 Mexico Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2022 - 2028, USD Million
TABLE 73 Mexico Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2018 - 2021, USD Million
TABLE 74 Mexico Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2022 - 2028, USD Million
TABLE 75 Mexico Attention Deficit Hyperactivity Disorder Market by Demographics, 2018 - 2021, USD Million
TABLE 76 Mexico Attention Deficit Hyperactivity Disorder Market by Demographics, 2022 - 2028, USD Million
TABLE 77 Mexico Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 78 Mexico Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 79 Rest of North America Attention Deficit Hyperactivity Disorder Market, 2018 - 2021, USD Million
TABLE 80 Rest of North America Attention Deficit Hyperactivity Disorder Market, 2022 - 2028, USD Million
TABLE 81 Rest of North America Attention Deficit Hyperactivity Disorder Market by Drug Type, 2018 - 2021, USD Million
TABLE 82 Rest of North America Attention Deficit Hyperactivity Disorder Market by Drug Type, 2022 - 2028, USD Million
TABLE 83 Rest of North America Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2018 - 2021, USD Million
TABLE 84 Rest of North America Attention Deficit Hyperactivity Disorder Market by Stimulants Type, 2022 - 2028, USD Million
TABLE 85 Rest of North America Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2018 - 2021, USD Million
TABLE 86 Rest of North America Attention Deficit Hyperactivity Disorder Market by Non-stimulants Type, 2022 - 2028, USD Million
TABLE 87 Rest of North America Attention Deficit Hyperactivity Disorder Market by Demographics, 2018 - 2021, USD Million
TABLE 88 Rest of North America Attention Deficit Hyperactivity Disorder Market by Demographics, 2022 - 2028, USD Million
TABLE 89 Rest of North America Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2018 - 2021, USD Million
TABLE 90 Rest of North America Attention Deficit Hyperactivity Disorder Market by Distribution Channel, 2022 - 2028, USD Million
TABLE 91 Key Information – Eli Lilly And Company
TABLE 92 Key Information – Pfizer, Inc.
TABLE 93 Key Information – Johnson & Johnson (Johnson & Johnson Services, Inc.)
TABLE 94 Key Information – Lupin Limited
TABLE 95 Key Information – Novartis AG
TABLE 96 Key Information – Takeda Pharmaceutical Company Limited
TABLE 97 Key information – Mallinckrodt PLC
TABLE 98 Key Information – Purdue Pharma L.P.
TABLE 99 Key Information – AYTU BIOPHARMA, INC.
TABLE 100 Key Information – Supernus Pharmaceuticals, Inc.
List of Figures
FIG 1 Methodology for the research